Bailard Inc. Invests $157,000 in Protara Therapeutics, Inc. (NASDAQ:TARA)

Bailard Inc. purchased a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 29,769 shares of the company’s stock, valued at approximately $157,000. Bailard Inc. owned 0.14% of Protara Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. grew its stake in shares of Protara Therapeutics by 40.8% during the third quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock valued at $328,000 after acquiring an additional 51,944 shares in the last quarter. XTX Topco Ltd acquired a new stake in Protara Therapeutics during the 3rd quarter valued at approximately $60,000. Finally, Geode Capital Management LLC increased its holdings in Protara Therapeutics by 21.0% during the 3rd quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock worth $311,000 after purchasing an additional 29,514 shares during the last quarter. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Stock Up 8.0 %

Shares of NASDAQ TARA opened at $3.63 on Thursday. The stock has a market capitalization of $74.89 million, a P/E ratio of -1.29 and a beta of 1.69. The stock’s 50 day moving average price is $4.63 and its two-hundred day moving average price is $3.39. Protara Therapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.09. On average, analysts anticipate that Protara Therapeutics, Inc. will post -3.32 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on TARA shares. Guggenheim reaffirmed a “buy” rating and issued a $20.00 target price on shares of Protara Therapeutics in a research report on Friday, December 6th. HC Wainwright reiterated a “buy” rating and set a $23.00 price objective on shares of Protara Therapeutics in a research note on Friday, December 6th.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.